Espervita Therapeutics, co-founded by Roger Newton, is a company primarily focused on the discovery of cancer therapies, particularly targeting liver cancer in areas with significant unmet medical needs. The company is set apart by its team's deep expertise in metabolic reprogramming, coupled with broad experience in drug discovery and development. Espervita's approach is rooted in developing metabolic reprogramming therapies utilized for cancer treatment, embodying the broader realm of medical therapeutics. Founded in 2018, the company operates within the Great Lakes and Midwestern regions of the US and has been actively seeking funding to propel its mission forward.
Roger Newton, the CEO of Espervita, holds a Ph.D. in nutrition, emphasizing lipid biochemistry and metabolic diseases from the University of California Davis. His postdoctoral fellowship was completed in the laboratory of Daniel Steinberg at the University of California San Diego School of Medicine. With a prolific contribution to the development and commercialization of novel therapies and diagnostics, Dr. Newton is lauded for his over 40 years of drug development experience, including the co-discovery of Lipitor®, a best-selling drug with nearly $150 billion in sales. He is currently an Adjunct Professor at the University of Michigan School of Medicine in the Department of Computational Medicine and Bioinformatics, showcasing his enduring commitment to advancing the medical field.
